Inicio
Fármacos Antitumorales
Luces y Sombras en las CDKs

8. Bibliografía


8.    Bibliografía

1.
Cavenee WK and White RL. Bases genéticas del cáncer. Investigación y Ciencia. 1995; 224, 44-51.
2.
Mitchison JM et al. The biology of the cell cycle. London: Cambridge University Press 1971.
3.
Cooper GM, Hausman RE. The Cell: a Molecular Approach 3ª Ed, Ed. Sinauer, 2004.
4.
Alberts B et al. Molecular Biology of the Cell. 4ª ed. Garland Science, 2002.
5.
Duke RC, Ojeius DM and Young, JDE. Suicidio celular en la salud y en la enfermedad. Investigación y Ciencia. 1997; 245, 44-52.
6.
Weinberg RA. Así se produce el cáncer. Investigación y Ciencia. 1996; 242, 10-18.
7.
Perucho M. Cáncer del fenotipo mutador de microsatélites. Investigación y Ciencia. 1998; 261, 46-53.
8.
Félix MA, Karsenti E. La división celular. Mundo Científico. 1995; 154(15): 245-249.
9.
Nurse, P. A long twentieth century of the cell cycle and beyond. Cell 2000; 100(1): 71-78.
10.
Murray AW and Kirschner MW. Control del ciclo celular. Investigación y Ciencia. 1991; 176, 26-33.
11.
Malumbres M. Revisiting the Cdk-centric view of the mammalian cell cycle. Cell Cycle. 2004; 4(2): 206-210.
12.
Sánchez I and Dynlacht BD. New insights into cyclins, CDKs, and cell cycle control. Seminars in Cell & Developmental Biology. 2005; 16: 311-321.
13.
Sherr CJ and Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13: 1501-1512.
14.
Martín A, Odajima J, Hunt SL et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1. Cancer Cell. 2005; 7: 591-598.
15.
Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2001; 2: 21-32.
16.
Noble M, Barrett P, Endicott J et al. Exploiting structural principles to design cyclin-dependent kinase inhibitors. Biochim. Biophys. Acta. 2005; 1754: 58-64.
17.
Haesslein JL and Julian N. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future. Curr. Topics Med. Chem. 2002; 2: 1037-1050.
18.
Malumbres M and Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sciences. 2005; 30(11): 630-641.
19.
Kong M, Barnes EA, Ollendorff V and Donoghue DJ. Cyclin F regulates the nuclear localization of cyclin B1through a cyclin-cyclin interaction. EMBO J. 2000; 19(6): 1378-1388.
20.
Kimura SH, Ikawa M, Ito A, Okabe M and Nojima H. Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene. 2001; 20: 3290-3300
21.
Chen HH, Wang YC and Fann MJ. Identification and characterization of the CDK12/Cyclin L1 Complex involved in alternative splicing regulation. Mol. Cell. Biol. 2006; 26(7): 2736-2745.
22.
Hirai H, Kawanishi N, Iwasawa Y. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Curr. Topics in Medicinal Chem. 2005; 5: 167-179.
23.
Nguyen TB, Manova K, Capodieci P et al. Characterization and expression of mammalian cyclin B3, a prepachytene meiotic cyclin. J. Biol. Chem. 2002; 277: 41960-41969.
24.
Ubersax JA, Woodbury EL, Quang PN et al. Targets of the cyclin-dependent kinase Cdk1. Nature. 2003; 425: 859-864.
25.
Nixon C et al. Expression of cell cycle associated proteins cyclin A, CDK-2, p27kip1 and p53 in equine sarcoids. Cancer Lett. 2005; 221: 237-245.
26.
Nixon C, Chambers G, Ellsmore V et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1. Cancer Cell. 2005; 7: 591-598.
27.
Malumbres M and Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nature Rev. Cancer. 2001; 222-231.
28.
Shao L, Hittelman WN, Lin J, Yang H, Ajani JA, Wu X. Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. Mutation Res. 2006; 602: 143-150.
29.
Rudner AD and Murray AW. The spindle assembly checkpoint. Curr. Opin. Cell Biol. 1996; 8: 773-780.
30.
Xu B, Kim S, and Kastan MB. Involvement of BRCA1 in S-phase and G2-phase checkpoints after ionizing radiation. Mol. Cell. Biol. 2001; 21: 3445-3450.
31.
Enders GH and Maude SL. Traffic safety for the cell: Influence of cyclin-dependent kinase activity on genomic stability. Gene 2006; 371: 1-6.
32.
Schwartz GK and Shah MA. Targeting the Cell Cycle: A New Approach to Cancer Therapy. J. Clin. Oncol. 2005; 23(36): 9408-9421.
33.
Shah MA, Schwartz GK. Cyclin dependent kinases as targets for cancer therapy. Update on Cancer Therapy I. 2006; 311-332.
34.
Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol. 2005; 5: 366-373.
35.
W?sierska-G?dek J, Gueorguieva M, Horky M. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol. J. Pharmacol. 2003; 55:895-902.
36.
Sandhu C and Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect Prev. 2000; 24:107-118.
37.
Wajed SA, Laird PW and DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann. Surg 2001; 234:10-20.
38.
Sutherland R and Musgrove E. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002; 4:14-7.
39.
Tetsu O and McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003; 3:233-245.
40.
Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin Oncol. 2006; 24(11): 1770-1783.
41.
Cai D, Latham VMJ, Zhang X and Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res. 2006; 66 (18): 9270-9280.
42.
Koumenis C and Giaccia A. Transformed cell require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol. Cell. Biol. 1997; 17: 7306-16.
43.
Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J. Cell Physiol. 2002; 190:160-9.
44.
Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sciences. 2002; 23(9):417-425.
45.
Sedlacek HH. Mecanisms of action of flavopiridol. Critical Rev. Oncology/Hematology. 2001; 38:139-170.
46.
Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor Flavopiridol. Clin. Cancer Res. 2004; 10:4270s-4275s.
47.
Senderowicz AM. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr. Opin. Cell Biol. 2004; 16: 670-678.
48.
Dai Y and Grant S. Cyclin-dependent kinase inhibitors. Curr. Opinion Pharmacol. 2003; 3: 362-370.
49.
Rossi K, Markwalder J, Seitz S et al. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modelling ad biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. J. Computer-Aied Mol. Design 2005; 19: 111-122.
50.
Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with stablished cytotoxic drugs in cancer chemotherapy. Drug Resistance Updates. 2003; 6: 15-26.